Details
Stereochemistry | EPIMERIC |
Molecular Formula | C16H18N2O7S2 |
Molecular Weight | 414.453 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@]2(NC(=O)C(C(O)=O)C3=CSC=C3)OC)C(O)=O
InChI
InChIKey=BVCKFLJARNKCSS-DWPRYXJFSA-N
InChI=1S/C16H18N2O7S2/c1-15(2)9(12(22)23)18-13(24)16(25-3,14(18)27-15)17-10(19)8(11(20)21)7-4-5-26-6-7/h4-6,8-9,14H,1-3H3,(H,17,19)(H,20,21)(H,22,23)/t8?,9-,14+,16-/m0/s1
Molecular Formula | C16H18N2O7S2 |
Molecular Weight | 414.453 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/27013887Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/22753
Sources: http://www.ncbi.nlm.nih.gov/pubmed/27013887
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/22753
Temocillin was marketed by Beecham Pharmaceuticals in the UK in the 1980s but achieved little commercial success and was withdrawn, though it remained available via the manufacturer’s medical department. Presently licensed to Eumedica, temocillin is being re-launched in the UK and Belgium for treating UTI, sepsis, and respiratory infections by ESBL (Extended-spectrum beta-lactamases) and AmpC-producing Enterobacteriaceae. It acts by inhibiting the synthesis of the peptidoglycan layer of bacterial cell walls. It irreversibly binds to the active site of specific transpeptidases and carboxypeptidases known as Penicillin Binding Proteins (PBP), preventing peptidoglycan production.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16531428
Curator's Comment: Temocillin was marketed by Beecham Pharmaceuticals in the UK in the 1980s but achieved little commercial success and was withdrawn
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Penicillin Binding Proteins Sources: http://www.ncbi.nlm.nih.gov/pubmed/3307621 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/27013887 |
Curative | Unknown Approved UseUnknown |
||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Temocillin in the treatment of pyelonephritis in children. | 1987 |
|
Probing the penicillin sidechain selectivity of recombinant deacetoxycephalosporin C synthase. | 2001 May |
|
In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. | 2006 Apr |
|
Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. | 2006 May |
|
Imported cutaneous melioidosis in traveler, Belgium. | 2007 Jun |
|
Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 Dec |
|
Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. | 2008 May |
|
Temocillin revived. | 2009 Feb |
|
In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria. | 2010 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/22753
Curator's Comment: Negaban (temocillin sodium) may be administered by intravenous injection, intermittent intravenous infusion or intramuscular injection.
1-2 g every 12 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6348653
Temocillin is a carboxypenicillin; a methoxy group in the 6-alpha position should confer to the molecule greater stability to beta-lactamases. 236 strains isolated from clinical specimens were tested. Enterobacteriaceae were very susceptible, MICs being generally less than or equal to 8 micrograms/ml and always less than 32 micrograms/ml. The activity of the drug was equal against the beta-lactamases producing strains
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:03:03 GMT 2023
by
admin
on
Sat Dec 16 17:03:03 GMT 2023
|
Record UNII |
03QB156W6I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01CA17
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
||
|
WHO-ATC |
J01CA17
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000082926
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
SUB10886MIG
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
C76858
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
171758
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
X-27
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
m10550
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1276310
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
266-184-1
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
TEMOCILLIN
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
DTXSID201009398
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
51817
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
37775
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
03QB156W6I
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
C031367
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
5097
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
DB12343
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
2587
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY | |||
|
66148-78-5
Created by
admin on Sat Dec 16 17:03:03 GMT 2023 , Edited by admin on Sat Dec 16 17:03:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENZYME->SUBSTRATE |
Leads to resistance to the antibiotic.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |